1. Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2014 
Frederick R. Appelbaum, Claudio Anasetti, Joseph H. Antin, Harold Atkins, Stella Davies, Steven Devine, Sergio Giralt, Helen Heslop, Ginna Laport, Stephanie J. Lee, Brent Logan, Marcelo Pasquini, Michael Pulsipher, Edward Stadtmauer, John R. Wingard, Mary M. Horowitz 
Biology of Blood and Marrow Transplantation 
Volume 21, Issue 2, Pages (February 2015)
DOI: /j.bbmt
Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1
The overall trial design depends on assignment to a high- or low-risk group based on GVHD grade and biomarkers. High-risk patients will be treated with prednisone, and new agents will be serially studied by addition to standard prednisone therapy. Low-risk patients will be randomized between a prednisone monotherapy or 1 of several single-agent nonsteroid alternatives.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions